Identificación de inhibidores de PI3Kα mediante diseño de farmacóforos y reposicionamiento farmacológico†

Autor: Paolo Wong Chero, Daniel Ramirez Lupuche, Richard Zapata Dongo, Stefany Infante Varillas, Juan Enrique Faya Castillo

Publikováno v: Horizonte Médico, Vol 24, Iss 3, p e2521 (2024)

Objetivo: PI3K es una de las proteínas más comunes que sufren mutaciones en el cáncer, ello genera que se altere su función en la regulación del metabolismo, la inmunidad, entre otros. A pesar de haberse identificado fármacos específicos para

Externí odkaz: https://doaj.org/article/e87d4e8ac91c4696a140ec17c9094b64

In silico modeling of protein-ligand binding

Autor: Varela Rial, Alejandro, 1993

Publikováno v: TDX (Tesis Doctorals en Xarxa)
TDR. Tesis Doctorales en Red
instname

The affinity of a drug to its target protein is one of the key properties of a drug. Although there are experimental methods to measure the binding affinity, they are expensive and relatively slow. Hence, accurately predicting this property with soft

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::c9ab0c5930fc7554efe829272ae4ba63
http://hdl.handle.net/10803/673579

Application of computational methods for anticancer drug discovery, design, and optimization

Autor: Liliana Marisol Moreno-Vargas, Sara Huerta-Yépez, Diego Prada-Gracia

Publikováno v: Boletín Médico Del Hospital Infantil de México (English Edition)
Boletin Medico Del Hospital Infantil De Mexico
Boletín Médico del Hospital Infantil de México, Vol 73, Iss 6, Pp 411-423 (2016)

Developing a novel drug is a complex, risky, expensive and time-consuming venture. It is estimated that the conventional drug discovery process ending with a new medicine ready for the market can take up to 15 years and more than a billion USD. Fortu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56baa677262301b6d20300d9b463cdd4
http://europepmc.org/articles/PMC7154613

Síntese e caracterização de novos adutos de Morita-Baylis-Hillman (AMBH) homodiméricos com potencial atividade anticâncer

Autor: Andrade, Sandro Dutra de

Publikováno v: Biblioteca Digital de Teses e Dissertações da UFPB
Universidade Federal da Paraíba (UFPB)
instacron:UFPB

In view of the promising bioactivity that the Morita-Baylis-Hillman adducts (AMBH) have presented as potential drug candidates and the possibility of developing new compounds belonging to this class with anticancer activity, this paper aims to synthe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3056::66411b996a4d297e16af49531ce5813c
https://repositorio.ufpb.br/jspui/handle/123456789/13047

Binding characteristics of sigma2 receptor ligands Características estruturais de ligantes do receptor sigma2

Autor: Richard A. Glennon

Publikováno v: Revista Brasileira de Ciências Farmacêuticas, Vol 41, Iss 1, Pp 1-12 (2005)

Sigma (sigma) receptors, once considered a type of opioid receptor, are now recognized as representing a unique receptive entity and at least two different types of sigma receptors have been identified: sigma1 and sigma2 receptors. Evidence suggests

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doajarticles::f3912d228dd5834d9b7ba980a5e76a8d
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-93322005000100002